$ALVO

Alvotech

Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines for patients worldwide. Its vertically integrated platform covers research and development, clinical testing, regulatory approvals, and manufacturing. Alvotech has five approved products and a pipeline of candidates addressing autoimmune, eye, respiratory, hematological and cancer conditions. Its marketed products include biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, sold under various regional brand names. Alvotech works with pharmaceutical partners to commercialize its products in global markets and does not currently have direct sales, marketing or distribution capabilities. It earns upfront and milestone payments and royalties through licensing arrangements, and typically manufactures and supplies products to its partners. Alvotech’s principal place of business is in Luxembourg; its headquarters and main manufacturing site are in Reykjavik, Iceland.

1
0
7

No SEC Form 4 filings for $ALVO in the last 30 days.

See all $ALVO insider activity →
Med

Alvotech Q3 2026 slides: manufacturing gains offset revenue miss

Alvotech (ALVO) reported Q3 2026 revenue of $112M, missing estimates of $139.22M. Shares fell 6.5% to $4.60. The company highlighted manufacturing improvements and strategic partnerships, but acknowledged lower-end full-year performance. Adjusted EBITDA rose 15% YoY to $78M, with cash balance declining to $61M.

Alvotech (ALVO): Financial results for 9M

Alvotech (ALVO) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing i

Alvotech earnings on deck as biosimilar FDA decisions loom

Alvotech SA reports Q3 earnings with analysts expecting a loss of $0.0186 per share and revenue of $139.2M, an improvement from Q2. The company awaits FDA decisions on biosimilars for Simponi, Eylea, and Prolia/Xgeva. Analysts rate the stock a Buy with a mean price target of $7.20, implying 47.5% upside. Recent estimate momentum has turned negative, with EPS and revenue estimates declining. Investors will focus on revenue growth, FDA decisions, and guidance for future profitability.

ALVO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 8 news stories mentioning ALVO (Alvotech). Coverage has skewed bearish: 1 bullish, 0 neutral, and 7 bearish.

Recent ALVO coverage spans earnings, regulation and financial news.

What's driving ALVO

AlphAI scores every news story that mentions ALVO with an AI model for sentiment and relevance, and aggregates insider trades from Alvotech's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ALVO

Score
$ALVOHighAI 8/10Earnings

Alvotech (ALVO): Financial results for 9M

Alvotech (ALVO) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing i

Alvotech earnings on deck as biosimilar FDA decisions loom

Alvotech SA reports Q3 earnings with analysts expecting a loss of $0.0186 per share and revenue of $139.2M, an improvement from Q2. The company awaits FDA decisions on biosimilars for Simponi, Eylea, and Prolia/Xgeva. Analysts rate the stock a Buy with a mean price target of $7.20, implying 47.5% upside. Recent estimate momentum has turned negative, with EPS and revenue estimates declining. Investors will focus on revenue growth, FDA decisions, and guidance for future profitability.

Here are Tuesday's biggest analyst calls: Nvidia, SpaceX, American Airlines, Ralph Lauren, MongoDB & more

Analysts made several calls: Morgan Stanley reiterated SpaceX as overweight, Cantor Fitzgerald initiated Ralph Lauren as overweight, Jefferies reiterated Tesla as hold, UBS downgraded Carlyle Group to neutral, Jefferies initiated Alvotech as buy, JPMorgan upgraded British American Tobacco to overweight, Jefferies upgraded Riot Platforms to buy, Citi upgraded Securitize to buy, UBS upgraded Millicom to buy, UBS upgraded Morgan Stanley Direct Lending Fund to buy, JPMorgan initiated Comfort…

Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win

AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.

Premarket movers: RTX rises, GE slips following quarterly results

U.S. stock index futures were mixed on Tuesday, with tech stocks under pressure. Halliburton (HAL) rose 3.4% after beating earnings expectations. Rapport Therapeutics (RPTX) surged 31.1% on positive Phase 2 trial results. NuScale Power (SMR) fell 6.5% after a downgrade. Akamai (AKAM) gained 2.2% following an upgrade. General Motors (GM) dropped 6.3% after disappointing investors with its outlook. Alvotech (ALVO) rose 7% after FDA approval. 3M (MMM) gained over 1% on Amazon partnership expansion.

Related tickers